Quetiapine

Quetiapine is a medication that affects chemical messengers in the brain, particularly serotonin and dopamine. It's most often prescribed to help manage symptoms of schizophrenia, bipolar disorder (including manic episodes and depression linked to bipolar), or to prevent mood episodes from coming back. Doctors sometimes call it an "atypical antipsychotic," which means it works differently from older medications in the same family and tends to cause fewer movement-related side effects.

Your family member might experience some common side effects like drowsiness, headache, dry mouth, dizziness, or constipation, especially when they first start taking it or if the dose changes. These effects don't happen to everyone, and they sometimes lessen over time. More serious side effects can include weight gain, a drop in blood pressure when standing up (which can lead to dizziness or falls), a faster heart rate, or changes in white blood cell counts. If you notice sudden dizziness when they stand, unexplained weight changes, or signs of infection like fever, it's worth discussing with their doctor.

Quetiapine stays in the body for around seven hours, but it's usually taken once or twice a day because the way it affects the brain lasts longer than that short half-life suggests. Some other medications—particularly certain antifungals, antibiotics, and HIV treatments—can increase quetiapine levels in the blood, so it's important that all prescribers know what else your family member is taking.

A Behaviour Support Practitioner will review this medication to determine whether it's being used to manage a mental health condition it's approved for, or whether it's primarily being used to manage behaviours of concern—which may meet the definition of chemical restraint under the NDIS Commission rules and require additional safeguards and regular review.

Quetiapine is a dibenzothiazepine derivative atypical antipsychotic with dual serotonin 5-HT₂ and dopamine D₁/D₂ receptor antagonism, exhibiting higher selectivity for serotonergic receptors—a profile that accounts for its low extrapyramidal liability relative to typical agents. It is PBS-listed for schizophrenia, acute mania, and maintenance treatment of bipolar I disorder (including as monotherapy or adjunct to lithium or valproate for prevention of manic, depressive, or mixed episode relapse), as well as for depressive episodes in bipolar disorder. Quetiapine has a pharmacokinetic half-life of approximately seven hours; however, clinical efficacy supports once- or twice-daily dosing with immediate-release formulations. Metabolism occurs primarily via CYP3A4, and co-administration with potent inhibitors (azole antifungals, macrolide antibiotics, protease inhibitors) can significantly elevate plasma concentrations, requiring dose adjustment. Common adverse effects include somnolence, dizziness, dry mouth, and constipation; serious concerns include orthostatic hypotension, tachycardia, weight gain, leukopenia, and falls—particularly relevant in older adults or those with cardiovascular or metabolic comorbidity.

When quetiapine is prescribed to manage behaviours of concern in an NDIS participant—rather than for a primary psychiatric indication—it meets the NDIS definition of a restrictive practice (chemical restraint) and triggers mandatory documentation and oversight requirements. The Behaviour Support Practitioner reviewing the prescription is verifying that the clinical indication, documented behavioural purpose (if applicable), dosing rationale, and monitoring plan align with the participant's current Behaviour Support Plan and that any behavioural intent has been reported to the NDIS Quality and Safeguards Commission as required under the Restrictive Practices rules. This is a statutory documentation process, not a clinical challenge; the BSP will seek confirmation of your prescribed indication, any behavioural goals documented in your notes, and the frequency of clinical review to satisfy Commission audit standards and ensure alignment between clinical intent and plan-of-record.